Skip to NavigationSkip to content

FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra

Published on 04/10/19 at 09:19am

AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra  (benralizumab) in a pre-filled, single-use auto-injector form, known as the Fasenra Pen.

The decision was based on Phase 1 and 3 data from two separate trials, and follows the product’s approval in the EU. Fasenra is currently approved in the US, EU, and Japan as an add-on treatment for eosinophilic asthma.

Data from these trials indicated that 97% of administrations in the 120 at-home patients, conducted by either the patients themselves or their caregiver, were successful at weeks 12 and 16. Furthermore, it was demonstrated that 96% of the auto-injectors that were returned were still functional at weeks 12 and 16.

“Fasenra is the only respiratory biologic that can be given every eight weeks after the initial loading-dose period,” explained Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca. “Today’s news means we can now offer Fasenra in an even more convenient way, giving US healthcare providers and patients the option of administering Fasenra at home or in a doctor’s office, and making treatment more accessible to patients with severe eosinophilic asthma.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches